The Food and Drug Administration is soliciting comments from the public—particularly veterinarians—related to the use of cannabis-derived products in animals, with an emphasis on CBD products. Information on general trends associated with CBD products, including usage trends ( e.g., product selection, indications, etc.), quality standards, use benefits, potential drug interactions, adverse events, safety problems, and toxicological concerns are specifically sought. This information will enhance the Center for Veterinary Medicine’s (CVM’s) knowledge of potential safety signals associated with these products, and aid their understanding of veterinarians’ experiences around cannabis-derived product use for their animal patients.
Either electronic or written comments on the request for information must be submitted by April 16, 2025.
Click here for instructions on submitting electronic comments.
Click here for instructions on submitting paper comments.
For more information, contact:
Katherine Breed
Center for Veterinary Medicine, Food and Drug Administration
12225 Wilkins Ave.
Rockville, MD 20852
301-796-9361
Katherine.Breed@fda.hhs.gov
Click here to read the full Federal Register Notice.